Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Effectiveness of the ChAdOx1 nCoV-19 Coronavirus Vaccine (CovishieldTM) in Preventing SARS-CoV2 Infection, Chennai, Tamil Nadu, India, 2021

by Arunachalam, Suresh , Venkatasamy, Vettrichelvan , Jagadeesan, Murugesan , Chinnappan, Prabhakaran , Kumar, Chethrapilly Purushothaman Girish , Bedi, Gagandeep Singh , Varghese, Alby John , Muni Krishnaiah, Murali Mohan , Sakthivel, Manikandanesan , Durai Samy, Augustine , Murali, Sharan , Govindasamy, Elavarasu , Shete, Anita , Dudhmal, Manisha , Kaur, Prabhdeep , Dhanapal, Sudha Rani , Gandhi, Punita Muni Krishna , Pattabi, Kamaraj , Sekar, Dhana Priya Vadhani , Thangaraj, Jeromie Wesley Vivian , Yadav, Pragya D , Ganeshkumar, Parasuraman , Majumdar, Triparna , Marappan, Prakash , Narnaware, Manish , Radhakrishnan, Vijayaprabha , Arjun, Jaganathan , Murhekar, Manoj , Sahay, Rima , Sivalingam, Azhagendran , Pounraj, Ezhil

in Age / AZD 1222 / ChAdOx1 nCoV-19 / Coronaviruses / COVID-19 / COVID-19 vaccines / Covishield / Genomic analysis / Households / Immunization / SARS-CoV-2 inactivated vaccines / Severe acute respiratory syndrome coronavirus 2 / vaccine effectiveness / Vaccines / Viral diseases

2022

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Effectiveness of the ChAdOx1 nCoV-19 Coronavirus Vaccine (CovishieldTM) in Preventing SARS-CoV2 Infection, Chennai, Tamil Nadu, India, 2021

2022

Confirm

Do you wish to request the book?

Effectiveness of the ChAdOx1 nCoV-19 Coronavirus Vaccine (CovishieldTM) in Preventing SARS-CoV2 Infection, Chennai, Tamil Nadu, India, 2021

2022

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Effectiveness of the ChAdOx1 nCoV-19 Coronavirus Vaccine (CovishieldTM) in Preventing SARS-CoV2 Infection, Chennai, Tamil Nadu, India, 2021

Arunachalam, Suresh,

Venkatasamy, Vettrichelvan,

Jagadeesan, Murugesan,

Chinnappan, Prabhakaran,

Kumar, Chethrapilly Purushothaman Girish,

Bedi, Gagandeep Singh,

Varghese, Alby John,

Muni Krishnaiah, Murali Mohan,

Sakthivel, Manikandanesan,

Durai Samy, Augustine,

Murali, Sharan,

Govindasamy, Elavarasu,

Shete, Anita,

Dudhmal, Manisha,

Kaur, Prabhdeep,

Dhanapal, Sudha Rani,

Gandhi, Punita Muni Krishna,

Pattabi, Kamaraj,

Sekar, Dhana Priya Vadhani,

Thangaraj, Jeromie Wesley Vivian,

Yadav, Pragya D,

Ganeshkumar, Parasuraman,

Majumdar, Triparna,

Marappan, Prakash,

Narnaware, Manish,

Radhakrishnan, Vijayaprabha,

Arjun, Jaganathan,

Murhekar, Manoj,

Sahay, Rima,

Sivalingam, Azhagendran,

Pounraj, Ezhil

2022

Overview

We estimated the effectiveness of two doses of the ChAdOx1 nCoV-19 (Covishield) vaccine against any COVID-19 infection among individuals ≥45 years in Chennai, Tamil Nadu, India. A community-based cohort study was conducted from May to September 2021 in a selected geographic area in Chennai. The estimated sample size was 10,232. We enrolled 69,435 individuals, of which 21,793 were above 45 years. Two-dose coverage of Covishield in the 18+ and 45+ age group was 18% and 31%, respectively. Genomic analysis of 74 out of the 90 aliquots collected from the 303 COVID-19-positive individuals in the 45+ age group showed delta variants and their sub-lineages. The vaccine’s effectiveness against COVID-19 disease in the ≥45 age group was 61.3% (95% CI: 43.6–73.4) at least 2 weeks after receiving the second dose of Covishield. We demonstrated the effectiveness of two doses of the ChAdOx1 vaccine against the delta variant in the general population of Chennai. We recommend similar future studies considering emerging variants and newer vaccines. Two-dose vaccine coverage could be ensured to protect against COVID-19 infection.

Share this book

Add to My Shelf

Publisher

MDPI AG,MDPI

Subject